Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to $7.9 million.

  • Usana Health Sciences' Depreciation & Amortization (CF) rose 12188.29% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 10814.75%. This contributed to the annual value of $14.5 million for FY2024, which is 1446.23% up from last year.
  • As of Q3 2025, Usana Health Sciences' Depreciation & Amortization (CF) stood at $7.9 million, which was up 12188.29% from $7.7 million recorded in Q2 2025.
  • Over the past 5 years, Usana Health Sciences' Depreciation & Amortization (CF) peaked at $8.3 million during Q1 2025, and registered a low of $2.5 million during Q1 2022.
  • Its 5-year average for Depreciation & Amortization (CF) is $4.1 million, with a median of $3.3 million in 2023.
  • As far as peak fluctuations go, Usana Health Sciences' Depreciation & Amortization (CF) tumbled by 1154.31% in 2023, and later soared by 16405.95% in 2025.
  • Over the past 5 years, Usana Health Sciences' Depreciation & Amortization (CF) (Quarter) stood at $3.2 million in 2021, then increased by 1.89% to $3.3 million in 2022, then decreased by 11.54% to $2.9 million in 2023, then skyrocketed by 37.33% to $4.0 million in 2024, then surged by 98.02% to $7.9 million in 2025.
  • Its last three reported values are $7.9 million in Q3 2025, $7.7 million for Q2 2025, and $8.3 million during Q1 2025.